India, Jan. 16 -- Shares of Atossa Therapeutics, Inc. (ATOS) are up 12% in pre-market trading today, as investors continue to focus on the company's advancing (Z)-endoxifen program and regulatory and clinical milestones expected in 2026.
Atossa is a clinical-stage biopharmaceutical company developing innovative oncology therapies, with a primary focus on breast cancer. Its lead program, (Z)-endoxifen, is a next-generation selective estrogen receptor modulator/degrader (SERM/D) designed to overcome limitations of tamoxifen and other endocrine therapies.
The therapy has shown encouraging activity across multiple early- and mid-stage studies, including signals of improved progression-free survival and durable disease control in estrogen rece...